公开(公告)号：US20220175842A1

公开(公告)日：2022-06-09

申请号：US16346806

申请日：2017-11-02

申请人： Darwin J. PROCKOP ,  Ashok K. SHETTY ,  Qianfa LONG ,  Dinesh UPADHYA ,  Bharathi HATTIANGADY ,  Dong-ki KIM

发明人： Darwin J. PROCKOP ,  Ashok K. SHETTY ,  Qianfa LONG ,  Dinesh UPADHYA ,  Bharathi HATTIANGADY ,  Dong-ki KIM

IPC分类号： A61K35/28 ,  A61P25/00 ,  A61K9/127

摘要： Disclosed are medicaments and methods for inhibiting brain inflammation and the cognitive memory loss attendant brain disease and damage in an animal. Status epilepticus, stroke and Alzheimer's disease are particular pathologies that are treated employing pharmaceutically acceptable preparations of the A1 exosomes. The preparations comprise an enriched population of A1 exosomes, such as exosomes derived from culture medium from mesenchymal stem cells. Medicaments and methods for inhibiting pattern recognition and/or memory impairment attendant a brain injury event or degenerative brain disease are also disclosed, comprising administering a pharmaceutically acceptable preparation of exosomes, particularly A1 exosomes, that are CD9− and that prevent the elevation of pro-inflammatory cytokines attendant a brain injury or disease.

公开(公告)号：US20190060368A1

公开(公告)日：2019-02-28

申请号：US16112282

申请日：2018-08-24

申请人： Ryang Hwa LEE ,  Joo Youn OH ,  Darwin J. PROCKOP ,  Dong-ki KIM ,  Taeko Shigemoto KURODA

发明人： Ryang Hwa LEE ,  Joo Youn OH ,  Darwin J. PROCKOP ,  Dong-ki KIM ,  Taeko Shigemoto KURODA

IPC分类号： A61K35/28 ,  A61K9/08 ,  A61P37/06

摘要： Pharmaceutically acceptable preparations of extracellular vesicles derived from activated MSCs are provided. These preparations are essentially free of MSCs, and demonstrate anti-inflammatory inhibiting pharmacological activity in vivo. Methods for using the preparations to prevent the onset of autoimmune diseases are presented. The MSC derived extracellular vesicles are provided in pharmaceutically acceptable preparations with a carrier, such as saline, and may be used to inhibit activation of antigen presenting cells. These preparations may also be used to suppress the development of T helper 1 (Th1) and Th17 cells. The disclosed activated MSC-derived extracellular vesicle preparations are essentially free of MSCs and other cells. Methods and preparations for treating and/or inhibiting the inflammatory response attendant organ transplant, diseases including human uveitis, type 1 diabetes, scleroderma, rheumatoid arthritis, lupus, Sjorgren's syndrome, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome, multiple sclerosis, anti-glomerular basement membrane disease, and pemphigoid diseases, are also provided.